نتائج البحث - Douglas Laird

تنقيح النتائج
  1. 1
    5-Hydroxymethylcytosine Profiling as an Indicator of Cellular State

    5-Hydroxymethylcytosine Profiling as an Indicator of Cellular State حسب A. Douglas Laird, John P. Thomson, David J. Harrison, Richard R. Meehan

    منشور في 2013
    احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248

    Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248 حسب Olga Potapova, A. Douglas Laird, Michelle Nannini, Angela Barone, Guangmin Li, Katherine G. Moss, Julie M. Cherrington, Dirk B. Mendel

    منشور في 2006
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study

    Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study حسب Sara M. Tolaney, Hovav Nechushtan, Ilan-Gil Ron, Patrick Schöffski, Ahmad Awada, Chris Yasenchak, A. Douglas Laird, Bridget O’Keeffe, Geoffrey I. Shapiro, Eric P. Winer

    منشور في 2016
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma

    Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma حسب Patrick Y. Wen, Antonio Omuro, Manmeet S. Ahluwalia, Hassan M. Fathallah‐Shaykh, Nimish Mohile, Joanne Lager, A. Douglas Laird, Jiali Tang, Jason Jiang, Coumaran Égile, Timothy F. Cloughesy

    منشور في 2015
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Phase I Safety and Pharmacokinetic Study of the PI3K/mTOR Inhibitor SAR245409 (XL765) in Combination with Erlotinib in Patients with Advanced Solid Tumors

    Phase I Safety and Pharmacokinetic Study of the PI3K/mTOR Inhibitor SAR245409 (XL765) in Combination with Erlotinib in Patients with Advanced Solid Tumors حسب Pasi A. Jänne, Roger B. Cohen, A. Douglas Laird, Sandrine Macé, Jeffrey A. Engelman, Rodrigo Ruiz-Soto, Kevin Rockich, Jianbo Xu, Geoffrey I. Shapiro, Pablo Martínez, Enriqueta Felip

    منشور في 2014
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors

    Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors حسب Kyriakos P. Papadopoulos, Josep Tabernero, Ben Markman, Amita Patnaik, Anthony W. Tolcher, José Baselga, Weiliang Shi, Coumaran Égile, Rodrigo Ruiz-Soto, A. Douglas Laird, Dale Miles, Patricia LoRusso

    منشور في 2014
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors

    Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors حسب Geoffrey I. Shapiro, Jordi Rodón, Cynthia Bedell, Eunice L. Kwak, José Baselga, Irene Braña, Shuchi S. Pandya, Christian Scheffold, A. Douglas Laird, Linh T. Nguyen, Yi Xu, Coumaran Égile, Gerald M. Edelman

    منشور في 2013
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study

    Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study حسب Daniel J. DeAngelo, Wendy Stock, Anthony S. Stein, Andrei R. Shustov, Michaela Liedtke, Charles A. Schiffer, Erik Vandendries, Katherine Liau, Revathi Ananthakrishnan, Joseph Boni, A. Douglas Laird, Luke Fostvedt, Hagop M. Kantarjian, Anjali S. Advani

    منشور في 2017
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial

    Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial حسب Elias Jabbour, Nicola Gökbuget, Anjali S. Advani, Matthias Stelljes, Wendy Stock, Michaela Liedtke, Giovanni Martinelli, Susan O’Brien, Tao Wang, A. Douglas Laird, Erik Vandendries, Alexander Neuhof, Kevin T. Nguyen, Naveen Dakappagari, Daniel J. DeAngelo, Hagop Kantarjian

    منشور في 2019
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

    Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth حسب F. Michael Yakes, Jason Chen, Jenny Tan, Toshihiro Yamaguchi, Yongchang Shi, Peiwen Yu, Fawn Qian, Felix Chu, Frauke Bentzien, Belinda Cancilla, Jessica Orf, Andrew You, A. Douglas Laird, Stefan Engst, Lillian Lee, Justin Lesch, Yu-Chien Chou, Alison Joly

    منشور في 2011
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS

    Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS حسب Michael R. Savona, Daniel A. Pollyea, Wendy Stock, Vivian G. Oehler, Mark A. Schroeder, Jeffrey E. Lancet, James McCloskey, Hagop M. Kantarjian, Weidong Wendy, M. Naveed Shaik, A. Douglas Laird, Mirjana Zeremski, Ashleigh O’Connell, Geoffrey Chan, Jorge E. Cortés

    منشور في 2018
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  12. 12
    Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome

    Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome حسب Jorge E. Cortés, Florian H. Heidel, Andrzej Hellmann, Walter Fiedler, B. Douglas Smith, Tadeusz Robak, Pau Montesinos, Daniel A. Pollyea, P. Desjardins, Oliver G. Ottmann, Weidong Wendy, M. Naveed Shaik, A. Douglas Laird, Mirjana Zeremski, Ashleigh O’Connell, Geoffrey Chan, Michael Heuser

    منشور في 2018
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  13. 13
    Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high‐risk MDS: Phase 2 study results

    Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high‐risk MDS: Phase 2 study results حسب Jorge E. Cortés, Benjamin D. Smith, Eunice S. Wang, Akil Merchant, Vivian G. Oehler, Martha Arellano, Daniel J. DeAngelo, Daniel A. Pollyea, Mikkael A. Sekeres, Tadeusz Robak, Weidong Wendy, Mirjana Zeremski, M. Naveed Shaik, A. Douglas Laird, Ashleigh O’Connell, Geoffrey Chan, Mark A. Schroeder

    منشور في 2018
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  14. 14
    Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high‐risk MDS: Phase 2 study results

    Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high‐risk MDS: Phase 2 study results حسب Cortes, Jorge E., Douglas Smith, B., Wang, Eunice S., Merchant, Akil, Oehler, Vivian G., Arellano, Martha, DeAngelo, Daniel J., Pollyea, Daniel A., Sekeres, Mikkael A., Robak, Tadeusz, Ma, Weidong Wendy, Zeremski, Mirjana, Naveed Shaik, M., Douglas Laird, A., O'Connell, Ashleigh, Chan, Geoffrey, Schroeder, Mark A.

    منشور في 2018
    احصل على النص الكامل احصل على النص الكامل احصل على النص الكامل
    نص
    أضف إلى المفضلة
    محفوظ في:
  15. 15
    Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma

    Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma حسب Lijun Zhou, Xian-De Liu, Mingli Sun, Xian Zhang, Polina German, Shanshan Bai, Zhiyong Ding, Nizar M. Tannir, Christopher G. Wood, Surena F. Matin, José A. Karam, Pheroze Tamboli, Kanishka Sircar, Priya Rao, Erinn B. Rankin, Douglas Laird, Anh Hoang, Cheryl L. Walker, Amato J. Giaccia, Eric Jonasch

    منشور في 2015
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  16. 16
    First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial

    First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial حسب Karim Fizazi, Arun Azad, Nobuaki Matsubara, Joan Carles, André P. Fay, Ugo De Giorgi, Jae Young Joung, Peter C.C. Fong, Éric Voog, Robert J. Jones, Neal D. Shore, Curtis Dunshee, Stefanie Zschäbitz, Jan Oldenburg, Dingwei Ye, Xun Lin, Cynthia G. Healy, Nicola Di Santo, A. Douglas Laird, Fabian Zohren, Neeraj Agarwal

    منشور في 2023
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  17. 17
    Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial

    Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial حسب Karim Fizazi, Arun Azad, Nobuaki Matsubara, Joan Carles, André P. Fay, Ugo De Giorgi, Jae Young Joung, Peter C.C. Fong, Éric Voog, Robert J. Jones, Neal D. Shore, Curtis Dunshee, Stefanie Zschäbitz, Jan Oldenburg, Dingwei Ye, Xun Lin, Cynthia G. Healy, Nicola Di Santo, A. Douglas Laird, Fabian Zohren, Neeraj Agarwal

    منشور في 2024
    احصل على النص الكامل احصل على النص الكامل
    Errata/Corrigenda
    أضف إلى المفضلة
    محفوظ في:
  18. 18
    Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer and changes in specific DNA repair genes: a plain language summary of the results from the TALAPRO-2 study

    Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer and changes in specific DNA repair genes: a plain language summary of the... حسب Karim Fizazi, Arun Azad, Nobuaki Matsubara, Joan Carles, André P. Fay, Ugo De Giorgi, Jae Young Joung, Peter C.C. Fong, Éric Voog, Robert J. Jones, Neal D. Shore, Curtis Dunshee, Stefanie Zschäbitz, Jan Oldenburg, Dingwei Ye, Xun Lin, Cynthia G. Healy, Nicola Di Santo, A. Douglas Laird, Fabian Zohren, Neeraj Agarwal

    منشور في 2025
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  19. 19
    Cabozantinib in Chemotherapy-Pretreated Metastatic Castration-Resistant Prostate Cancer: Results of a Phase II Nonrandomized Expansion Study

    Cabozantinib in Chemotherapy-Pretreated Metastatic Castration-Resistant Prostate Cancer: Results of a Phase II Nonrandomized Expansion Study حسب Matthew R. Smith, Christopher J. Sweeney, Paul G. Corn, Dana E. Rathkopf, David C. Smith, Maha Hussain, Daniel J. George, Celestia S. Higano, Andrea Harzstark, Oliver Sartor, Nicholas J. Vogelzang, Michael S. Gordon, Johann S. de Bono, Naomi B. Haas, Christopher J. Logothetis, Aymen Elfiky, Christian Scheffold, A. Douglas Laird, Frauke Schimmöller, Ethan Basch, Howard I. Scher

    منشور في 2014
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  20. 20
    The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models

    The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models حسب Paul Foster, Toshihiro Yamaguchi, Pin P. Hsu, Fawn Qian, Xiangnan Du, Jianming Wu, Kwang‐Ai Won, Peiwen Yu, Christopher T. Jaeger, Wentao Zhang, Charles K. Marlowe, Paul Keast, Wendy Abulafia, Jason Chen, Jenny Young, Artur Płonowski, F. Michael Yakes, Felix Chu, Kelly Engell, Frauke Bentzien, Sanh T. Lam, Stephanie Dale, Olivia Yturralde, David J. Matthews, Peter Lamb, A. Douglas Laird

    منشور في 2015
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: